HIV Infections
Conditions
Keywords
Thymopentin, Acquired Immunodeficiency Syndrome
Brief summary
Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Interventions
DRUGThymopentin
Sponsors
Immunobiology Research Institute
Study design
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Treatment: Allowed: * Aerosolized pentamidine. Prior Medication: Allowed: * Aerosolized pentamidine.
Exclusion criteria
Co-existing Condition: Patients with the following are excluded: * AIDS as defined by the CDC (except for those with HIV wasting syndrome). * Significant hepatic disease. * Thrombocytopenia (\< 75000 platelets/mm3). * Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to entry. * Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. * Known hypersensitivity to thymopentin. Prior Medication: Excluded within 30 days of study entry: * Immunomodulatory or experimental therapy. * Excluded within 90 days of study entry: * Zidovudine (AZT). Patients must not have: * AIDS as defined by the CDC (except for those with HIV wasting syndrome). * Significant hepatic disease. * Thrombocytopenia (\< 75000 platelets/mm3). Patients with the following conditions are included: * Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. * HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions. * HIV wasting syndrome. * Must voluntarily sign consent. History of intravenous drug abuse.
Countries
United States
Outcome results
None listed